Lilly’s Weight-Loss Machine Gets Even Bigger
Eli Lilly reported Q3 revenue of $24.4B, up 39% YoY, driven by Mounjaro and Zepbound, which together generated $16B. Adjusted earnings were $7.48 per share. Lilly raised full-year revenue guidance to $91B-$92B. Shares rose on strong demand for GLP-1 drugs, despite slower-than-expected sales of obesity pill Foundayo.
How this was made
The 30-second read
Why it matters
The guidance raise is likely to attract buying interest, especially from investors seeking exposure to high‑growth biotech.
Market read
First‑report earnings with strong guidance lift; high relevance for biotech and broader market participants.
What to watch
Acquired R&D charges and potential pricing headwinds could temper earnings momentum.
Background
Eli Lilly's obesity franchise, led by Mounjaro and Zepbound, continues to outpace expectations, driving a significant revenue surge.
Ticker impact
Eli Lilly reported Q3 revenue of $24.4B beating estimates and raised full-year revenue guidance to $91‑$92B, prompting a sharp share price jump.
upward pressure as investors price in higher revenue outlook
The guidance increase is a fresh, material development for a large‑cap pharma, and the share price already reacted positively.
Market effects
Boosts outlook for the obesity/diabetes therapeutic sector and may lift peers like Novo Nordisk.
Strengthens US biotech sentiment and could lift broader US pharma indices.
Highlights growing global demand for GLP‑1 therapies, influencing worldwide biotech valuations.
Counterpoint
If pricing pressure intensifies or competition from oral agents accelerates, the guidance may be overly optimistic.
Key entities
- companyEli Lilly
Pharmaceutical company reporting earnings and guidance.
